Jaivir Rathore, MD
Epilepsy · Orlando, FLNPI 1932355971
Payments from drug & device makers
Across 442 payments — averaging $86.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$19K
- SK Life Science, Inc.$6K
- Livanova USA, Inc.$5K
- UCB, Inc.$1K
- AbbVie$828
- Neurocrine Biosciences, Inc.$515
- plus $6K from 48 others
Across 1 payment — averaging $14.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$15
What the payments were for
- Consulting fees$4601%
- Speaking & faculty fees$25,19566%
- Travel & lodging$1,6964%
- Food & beverage$10,81728%
- Education$1700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$17,680
- XCOPRI$5,671
- VNS - Sentiva$1,878
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$1,656
- VNS Therapy$1,230
- QULIPTA$242
- UBRELVY$242
- INFINITY$237
- DAYBUE$202
- CREXONT$124
- Fintepla$123
- Auvelity$122
- APTIOM$120
- Fycompa$117
- Nayzilam$112
- AIMOVIG$110
- INGREZZA$107
How this compares
$38,337 in reported general payments places this provider in the 70th percentile of 23 epilepsy providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| WakixPitolisant Hcl | 12 | $158,680 |
| IngrezzaValbenazine Tosylate | 12 | $115,632 |
| AustedoDeutetrabenazine | 13 | $65,163 |
| Nurtec OdtRimegepant Sulfate | 26 | $52,542 |
| BriviactBrivaracetam | 33 | $51,840 |
| BotoxOnabotulinumtoxina | 23 | $42,402 |
| XcopriCenobamate | 15 | $29,112 |
| QuliptaAtogepant | 25 | $28,521 |
| UbrelvyUbrogepant | 17 | $18,402 |
| RytaryCarbidopa/Levodopa | 19 | $14,431 |
| Emgality SyringeGalcanezumab-Gnlm | 14 | $13,689 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $11,074 |
| Atomoxetine Hcl | 73 | $9,013 |
| Memantine Hcl | 209 | $6,825 |
| Lamotrigine ErLamotrigine | 11 | $5,155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Harmony Biosciences LLCWakix | $307 | $158,68012 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $515 | $115,63212 claims |
| AbbVieBotox, Qulipta, Ubrelvy | $828 | $89,32565 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $18,931 | $65,16313 claims |
| PfizerNurtec Odt | $220 | $52,54226 claims |
| UCB, Inc.Briviact | $1,144 | $51,84033 claims |
| SK Life Science, Inc.Xcopri | $6,210 | $29,11215 claims |
| Amneal Pharmaceuticals LLCRytary | $228 | $14,43119 claims |
| Upsher-smith Laboratories LLCTopiramate | $27 | $35226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 23 epilepsy providers in Florida.
Other epilepsy in Orlando
- Dipali NemadeOrlando$38K
- Bruno MatonOrlando$2K
- Andrew LermanMiami$4.5M
- Brian CostellBoca Raton$4M
- William TatumJacksonville$574K
- Alberto Pinzon ArdilaMiami$351K
- Yue WangGainesville$45K
- Miguel Melo-BicchiMiami$44K
- Mohamed NasserWeston$28K
- Jean CibulaGainesville$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.